Bone scans, bisphosphonates, and a lack of acute changes within the mandible.
OBJECTIVE
The etiology of osteonecrosis of the jaw is poorly understood, but preferential mandibular uptake of intravenous bisphosphonates (IVBPs) has been implicated. We examined this association within a prospective study assessing the effect of IVBPs on radionuclide bone scanning.


METHODS
Women with at least 3 osseous breast metastases on bone scanning and previous IVBP use within 8 weeks were eligible for the present study. After the first clinically indicated bone scan, the patients received zoledronic acid within 72 hours and underwent a second bone scan within another 72 hours. The regions of interest on the bone scan were read in triplicate, and the mean count per pixel was calculated for the mandible (C(M)), left femur (C(FL)), right femur (C(FR)), and thigh (C(B)). The mandibular bone turnover (MBT) was quantified as the ratio of (C(M) - C(B))/(C(F) - C(B)), where C(F) = (C(FL) + C(FR)/2). The MBT was compared before and after IVBP use.


RESULTS
A total of 10 patients were enrolled (median age 51 years, range 40 to 71); none had known osteonecrosis of the jaw. Of the 10 patients, 8 had paired bone scans available for analysis. The previous zoledronic acid exposure was 48.6 mg (range 24 to 148) for a median of 13 months (range 6 to 35). The baseline mean MBT ratio was 2.33 (range 0.88 to 4.22). After IVBP administration, the mean MBT ratio was statistically unchanged at 2.23 (range 1.05 to 3.09). The MBT had declined in 4 patients and increased in 4. Only 1 patient had had an MBT of less than 1.0 before IVBP use, and no patient had an MBT ratio of less than 1.0 after IVBP use.


CONCLUSIONS
The mandibular region appears to be a site of increased uptake of technetium-99m bound to methylene diphosphonate-technetium. Acute changes in bisphosphonate binding in the mandible were not observed in our patients receiving chronic IVBP therapy.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA. morrisp1@mskcc.org
Patrick G
PG
Morris
Clifford
C
Hudis
Jorge
J
Carrasquillo
Steven
S
Larson
Ravinder K
RK
Grewal
Catherine
C
Van Poznak
D000328:Adult; D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000378:metabolism*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D004164:Diphosphonates / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D005269:Femur / Q000000981:diagnostic imaging / Q000378:metabolism; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000378:metabolism; D007262:Infusions, Intravenous; D008334:Mandible / Q000000981:diagnostic imaging* / Q000378:metabolism; D008875:Middle Aged; D011446:Prospective Studies; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D016037:Single-Blind Method; D013669:Technetium Tc 99m Medronate; D013848:Thigh / Q000000981:diagnostic imaging; D013997:Time Factors; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D019275:Radiopharmaceuticals; D000077211:Zoledronic Acid; D013669:Technetium Tc 99m Medronate